A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jack Gilleland
| Share Statistics | BLRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $13.7 | $252.6 | 8% |
|
| Shares Out (Mil) | 2,660.2 | 52.3 | 98% |
|
| Institutional Ownership | 89.5% | 92.1% | 57% |
|
| Float (Mil) | 2,508.3 | 40.2 | 96% |
|
| Beta | 0.62 | 0.95 | 36% |
|
| Avg Daily Volume (000s) | 11 | 455 | 17% |
|
| Price Change (52-week) |
(29.7%) | 52.9% | 25% |
|
| Growth | BLRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 47.5% | (9.9%) | 93% |
|
| EPS (5yr) | 14.9% | 16.0% | 55 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (14.9%) | (15.6%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.300) | ($0.930) | ($0.640) | |
| Month Ago EPS | ($0.300) | ($0.930) | ($0.640) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($0.320) | ($1.090) | ($0.670) | |
| Year/Year Chg | 29,900% | na | na | |
| Financials | BLRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $38 | 3% |
|
| Net Income (TTM) (Mil) | ($8) | ($43) | 31% |
|
| EPS (TTM) | ($0.003) | ($1.600) | 39% |
|
| Operating Cash Flow (TTM) (Mil) | ($8) | ($31) | 21% |
|
| Net Cash Flow (TTM) (Mil) | ($7) | $5 | 33% |
|
| Long-Term Debt (Q1) (Mil) | $4 | $5 | 24% |
|
| Enterprise Value (Q1) (Mil) | $11 | $180 | 8% |
|
| Valuation | BLRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 282.00 | 2.56 | 100% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | BLRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 79.2% | 63.8% | 88% |
|
| Net Margin | (563.7%) | (67.3%) | 1% |
|
| ROA | (19.2%) | (49.8%) | 21% |
|
| ROE | (42.1%) | (55.5%) | 17% |
|
| Liabilities to Assets | 46.3% | 30.3% | 37% |
|
| F-Score | 3 | 3 | 19% |
|
BioLineRx Ltd. did not pass any screens on 7/31/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
